Flaxseed alone or in combination with tamoxifen inhibits MCF-7 breast tumor growth in ovariectomized athymic mice with high circulating levels of estrogen

Experimental Biology and Medicine

Volumn 232, Issue 8, 2007, Pages 1071-1080

  Chen, Jianmin ^a   Power, Krista A ^a   Mann, Jaskaren ^a   Cheng, Astor ^a   Thompson, Lilian U ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Athymic mice; Breast cancer; Flaxseed; Lignan; Tamoxifen

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; LINSEED OIL; PROGESTERONE RECEPTOR; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST TUMOR; CANCER GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ESTROGEN BLOOD LEVEL; HUMAN; HUMAN CELL; LINSEED; MOUSE; NONHUMAN; NUDE MOUSE; OVARIECTOMY; PROTEIN EXPRESSION; UTERUS WEIGHT;

ALPHA-LINOLENIC ACID; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; FLAX; FOOD, FORMULATED; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGNANS; MICE; MICE, INBRED BALB C; MICE, NUDE; ORGAN SIZE; OVARIECTOMY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; TAMOXIFEN; UTERUS;

MAMMALIA; MUS;

EID: 34548443813     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0702-RM-36     Document Type: Article

References (57)

1. Jordan VC. The past, present, and future of selective estrogen receptor modulation. Ann N Y Acad Sci 949:72-79, 2001.
2. Carrizosa DR, Carey LA. Adjuvant systemic therapy in young women. Breast Dis 23:67-71, 2005.
3. MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 50:151-196, 1998.
4. Headley JA, Theriault RL, LeBlanc AD, Vassilopoulou-Sellin R, Hortobagyi GN. Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy. Cancer Invest 16:6-11, 1998.
5. Shapiro CL, J. Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19:3306-3311, 2001.
6. Eisenberg DM, Davis RB, Ettner SL. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280:1569-1575, 1998.
7. Vande Creek L, Rogers E, Lester J. Use of alternative therapies among breast cancer outpatients compared with the general population. Alter Ther Health Med 5: 71-76, 1999.
8. Weiger WA, Smith M, Boon H, Richardson MA, Kaptchuk TJ, Eisenber DM. Advising patients who seek complementary and alternative medical therapies for cancer. Ann Intern Med 137:889-903, 2002.
9. Boon HS, Olatunde F, Zick. Trends in complementary/alternative medicine use by breast cancer survivors: Comparing survey data from 1998 and 2005. BMC Women's Health 7:4, 2007.
10. Gardiner P, Legedza A, Woods C, Phillips RS, Kemper KJ. Herb use among health care professionals enrolled in an online curriculum on herbs and dietary supplements. J Herb Pharmacother 6:51-64, 2006.
11. Thompson LU, Seidl MM, Richard SE, Orcheson LJ, Fong HH. Antitumorigenic effect of a mammalian lignan precursor from flaxseed. Nutr Cancer 26:159-165, 1996.
12. Thompson LU. Flaxseed, lignans, and cancer. In: Thompson LU, Cunnane SC, Eds. Flaxseed in Human Nutrition (2nd ed). Champaign: AOCS Press, pp194-222, 2003.
13. Bougnoux P, Chajes V. a-Linolenic acid and cancer. In: Thompson LU, Cunnane SC, Eds. Flaxseed in Human Nutrition (2nd ed). Champaign: AOCS Press, pp232-244, 2003.
14. Mueller SO, Simon S, Chae K, Metzler M, Korach KS. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol Sci 2004;80:14-25.
15. Chen J, Hui E, Ip T, Thompson LU. Dietary flaxseed enhances the inhibitory effect of tamoxifen on the growth of estrogen-dependent human breast cancer (mcf-7) in nude mice. Clin Cancer Res 10:7703-7711, 2004.
16. Chen J, Stavro PM, Thompson LU. Dietary flaxseed inhibits human breast cancer growth and metastasis and downregulates expression of insulin-like growth factor and epidermal growth factor receptor. Nutr Cancer 43:187-192, 2002.
17. Dabrosin C, Chen J, Wang L, Thompson LU. Flaxseed inhibits metastasis and decreases extracellular vascular endothelial growth factor in human breast cancer xenografts. Cancer Lett 185:31-37, 2002.
18. Thompson LU, Chen JM, Li T, Strasser-Weippl K, Goss PE. Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer. Clin Cancer Res 11:3828-3835, 2005.
19. Olfer ED, Cross BM, McWilliam AA, Eds. The Guide to the Care and Use of Experimental Animals, Vol 1 (2nd ed). Ottawa: Canadian Council on Animal Care, 1993.
20. Reeves PG, Nielsen FH, Fahey Jr GC. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 123:1939-1951, 1993.
21. Thompson LU, Rickard SE, Orcheson LJ, Seidl MM. Flaxseed and its lignan and oil components reduce mammary tumor growth at a late stage of carcinogenesis. Carcinogenesis 17:1373-1376, 1996.
22. Rickard SE, Yuan YV, Chen J, Thompson LU. Dose effects of flaxseed and its lignan on N-methyl-N-nitrosourea-induced mammary tumorigenesis in rats. Nutr Cancer 35:50-57, 1999.
23. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155-168, 1998.
24. Wang C, Kurzer MS. Phytoestrogen concentration determines effects on DNA synthesis in human breast cancer cells. Nutr Cancer 28:236-247, 1997
25. Mousavi Y, Adlercreutz H. Enterolactone and estradiol inhibit each other's proliferative effect on MCF-7 breast cancer cells in culture. J Steroid Biochem Mol Biol 41:615-619, 1992.
26. Welshons WV, Murphy CS, Koch R, Calaf G, Jordan VC. Stimulation of breast cancer cells in vitro by the environmental estrogen enterolactone and the phytoestrogen equol. Breast Cancer Res Treat 10:169-175, 1987.
27. Saarinen NM, Penttinen PE, Smeds AI, Hurmerinta TT, Makela SI. Structural determinants of plant lignans for growth of mammary tumors and hormonal responses in vivo. J Steroid Biochem Mol Biol 93:209-219. 2005.
28. Saarinen NM, Huovinen R, Warri A, Makela SI, Valentin-Blasini L, Sjoholm R, Ammala J, Lehtila R, Eckerman C, Collan YU, Santti RS. Enterolactone inhibits the growth of 7,12-dimethylbenz(a)anthracene-induced mammary carcinomas in the rat. Mol Cancer Ther 1:869-876, 2002.
29. Saarinen NM, Huovinen R, Warri A, Makela SI, Valentin-Blasini L, Needham L, Eckerman C, Collan YU, Santti R. Uptake and metabolism of hydroxymatairesinol in relation to its anticarcinogenicity in DMBA-induced rat mammary carcinoma model. Nutr Cancer 41:82-90, 2001.
30. Saarinen NM, Power K, Chen J, Thompson LU. Flaxseed attenuates the tumor growth stimulating effect of soy protein in ovariectomized athymic mice with MCF-7 human breast cancer xenografts. Int J Cancer 119:925-931, 2006.
31. Power KA, Saarinen NM, Chen JM, Thompson LU. Mammalian lignans enterolactone and enterodiol, alone and in combination with the isoflavone genistein, do not promote the growth of MCF-7 xenografts in ovariectomized athymic nude mice. Int J Cancer 118:1316-1320, 2006.
32. Jungerstrom MB, Thompson LU, Dabrosin C. Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of VEGF in human breast cancer xenografts in vivo. Clin Cancer Res 13:1061-1067, 2007.
33. Pink JJ, Jordan VC. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 56:2321-2330, 1996.
34. Arafah BM, Finegan HM, Roe J, Manni A, Pearson OH. Hormone dependency in N-nitrosomethylurea-induced rat mammary tumors. Endocrinology 111:584-588, 1982.
35. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21:1973-1979, 2003.
36. Bjornstrom L, Sjoberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 19:833-842, 2005.
37. Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 12:S99-S111, 2005.
38. Detre S, Riddler S, Salter J, A'Hern R, Dowsett M, Johnston SR. Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model. Cancer Res 63:6516-6522, 2003.
39. Rickard SE, Yuan YV, Thompson LU. Plasma insulin-like growth factor I levels in rats are reduced by dietary supplementation of flaxseed or its lignan secoisolariciresinol diglycoside. Cancer Lett 161:47-55, 2000.
40. Chong YM, Colston K, Jiang WG, Sharma AK, Mokbel K. The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue. Breast Cancer Res Treat 99:275-288, 2006.
41. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393-1396, 1998.
42. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P. Activation of the estrogen receptor through phosphorylation by mitogen activated protein kinase. Science 270:1491-1494, 1995.
43. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 277:1508-1510, 1997.
44. Garvin S, Dabrosin C. Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo. Cancer Res 63:8742-8748, 2003.
45. Stoll BA. n-3 fatty acids and lipid peroxidation in breast cancer inhibition. Br J Nutr 87:193-198, 2002.
46. Rose DP. Effects of dietary fatty acids on breast and prostate cancers: evidence from in vitro experiments and animal studies. Am J Clin Nutr 66:1513S-1522S, 1997.
47. Rose DP. Dietary fatty acids and prevention of hormone-responsive cancer. Proc Soc Exp Biol Med 216:224-233, 1997.
48. El-Sohemy A, Archer MC. Regulation of mevalonate synthesis in rat mammary glands by dietary n-3 and n-6 polyunsaturated fatty acids. Cancer Res 57:3685-3687, 1997.
49. DeGraffenried LA, Friedrichs WE, Fulcher L, Fernandes G, Silva JM, Peralba JM, Hidalgo M. Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity. Ann Oncol 14:1051-1056, 2003.
50. Liu Z, Saarinen NM, Thompson LU. Sesamin is one of the major precursors of mammalian lignans in sesame seed (Sesamum indicum) as observed in vitro and in rats. J Nutr 136:906-912, 2006.
51. Sacco SM, Power KA, Chen J, Ward WE, Thompson LU. Interaction of sesame seed and tamoxifen on tumor growth and bone health in athymic mice. Exp Biol Med (Maywood) 232:754-761, 2007.
52. Power KA, Ward WE, Chen JM, Saarinen NM, Thompson LU. Flaxseed and soy protein isolate, alone and in combination, differ in their effect on bone mass, biomechanical strength, and uterus in ovariectomized nude mice with MCF-7 human breast tumor xenografts. J Toxicol Environ Health A 2007 (in press).
53. Power KA, Ward WE, Chen JM, Saarinen NM, Thompson LU. Genistein alone and in combination with the mammalian lignans enterolactone and enterodiol induce estrogenic effects on bone and uterus in a postmenopausal breast cancer mouse model. Bone 39:117-124, 2006.
54. Chen J, Wang L, Thompson LU. Flaxseed and its components reduce metastasis after surgical excision of solid human breast tumor in nude mice. Cancer Lett 234:168-175, 2006.
55. Angelova V, Ivanova R, Delibaltova V, Ivanov K. Bio-accumulation and distribution of heavy metals in fibre crops (flax, cotton and hemp). Ind Corps Prod 19:197-205, 2004.
56. Hocking PJ, McLaughlin MJ. Genotypic variation in cadmium accumulation by seed of linseed, and comparison with seed of some other crop species. Austr J Agric Res 52:427-433, 2006.
57. Johnson MD, Kenney N, Stoica A, Hilakivi-Clarke L, Singh B, Chepko G, Clarke R, Sholler PF, Lirio AA, Foss C, Reiter R, Trock B, Paik S, Martin MB. Cadmium mimics the in vivo effects of estrogen in the uterus and mammary gland, Nat Med 9:1081-1084, 2003.